Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
Zinbryta | Daclizumab beta | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecfidera | Dimethyl fumarate | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
Aubagio | Teriflunomide | Multiple sclerosis, relapsing-remitting | Do not list at the submitted price | Complete | ||
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | |||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Gilenya | Fingolimod | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
Soliris | eculizumab | Myasthenia Gravis (gMG), adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Poteligeo | mogamulizumab | mycosis fungoides (MF), Sézary syndrome (SS) | Reimburse with clinical criteria and/or conditions | Complete |